Основная статистика
| LEI | 549300NVPLITUM6URT02 |
| CIK | 872912 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Delcath Systems, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 15, 2025 |
As filed with the Securities and Exchange Commission on August 15, 2025 S-8 As filed with the Securities and Exchange Commission on August 15, 2025 Registration No. |
|
| August 15, 2025 |
AMENDED AND RESTATED BYLAWS DELCATH SYSTEMS, INC. (A DELAWARE CORPORATION) SECTION 1. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF DELCATH SYSTEMS, INC. (A DELAWARE CORPORATION) SECTION 1. OFFICES Section 1.1 Registered Office. The registered office of Delcath Systems, Inc. (the “Corporation”) in the State of Delaware and the name of the Corporation’s registered agent at such address shall be as set forth in the certificate of incorporation of the Corporation (as the same may |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Delcath Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-16133 06-1245881 (State or other jurisdiction of incorporation) (Commission F |
|
| August 15, 2025 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 DELCATH SYSTEMS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Omnibus 2020 Equity Incentive Plan Common Stock, par value $0.01 per share Other 2,200,000 $ 10.28 $ 22,616,000 |
|
| August 6, 2025 |
Delcath Systems Inc. 2020 Omnibus Equity Incentive Plan, as amended. DELCATH SYSTEMS, INC. 2020 OMNIBUS EQUITY INCENTIVE PLAN (As adopted by Board of Directors on September 30, 2020 and approved by stockholders on November 23, 2020) (As amended by the Board of Directors on March 30, 2021 and approved by stockholders on May 6, 2021) (As subsequently amended by the Board of Directors on April 17, 2023 and approved by stockholders on June 12, 2023) (As subsequently am |
|
| August 6, 2025 |
Exhibit 99.1 Delcath Systems Reports Second Quarter 2025 Results and Business Highlights Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY – August 6, 2025, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 DELCATH SYSTEMS, INC. |
|
| August 6, 2025 |
Delcath Systems, Inc. 2021 Employee Stock Purchase Plan, as amended. DELCATH SYSTEMS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN (As amended by the Board of Directors on February 7, 2025, and approved by the stockholders on May 15, 2025) The purpose of the Delcath Systems, Inc. 2021 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Delcath Systems, Inc. (the “Company”) and each Designated Subsidiary (as defined in Section 11) with opportunit |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-16133 DEL |
|
| August 6, 2025 |
2023 Inducement Plan, as amended. DELCATH SYSTEMS, INC. 2023 INDUCEMENT PLAN (Adopted by Board of Directors on December 5, 2023) (Amended and Restated by the Board of Directors on February 5, 2025) (Amended and Restated by the Board of Directors on May 14, 2025) General. a.Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants |
|
| May 22, 2025 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 DELCATH SYSTEMS, INC. |
|
| May 22, 2025 |
Exhibit 99.1 Delcath Systems Issues Full Year 2025 Guidance 2025 Full Year Total Revenue Guidance of $94 to $98 million Delcath Announces Plan to Enter into National Medicaid Drug Rebate Agreement QUEENSBURY, NY – May 22, 2025, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, toda |
|
| May 16, 2025 |
Delcath Systems, Inc. 2021 Employee Stock Purchase Plan, as amended Exhibit 10.2 Appendix B DELCATH SYSTEMS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Delcath Systems, Inc. 2021 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Delcath Systems, Inc. (the “Company”) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, par value $0.01 per share (the |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Delcath Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-16133 06-1245881 (State or other jurisdiction of incorporation) (Commission File |
|
| May 16, 2025 |
Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended Exhibit 10.1 Appendix A DELCATH SYSTEMS, INC. 2020 OMNIBUS EQUITY INCENTIVE PLAN (As adopted by Board of Directors on September 30, 2020 and approved by stockholders on November 23, 2020) (As amended by the Board of Directors on March 30, 2021 and approved by stockholders on May 6, 2021) (As subsequently amended by the Board of Directors on April 17, 2023 and approved by stockholders on June 12, 2 |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 DELCATH SYSTEMS, INC. |
|
| May 8, 2025 |
Exhibit 99.1 Delcath Systems Reports First Quarter 2025 Results and Business Highlights Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY – May 8, 2025, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-16133 DE |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive Additional Materials o Soliciting Material Under § 240. |
|
| April 1, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Under § 240. |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 DELCATH SYSTEMS, INC. |
|
| March 21, 2025 |
Letter from Marcum LLP to the Securities and Exchange Commission dated March 18, 2025. Exhibit 16.1 March 18, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Delcath Systems, Inc. under Item 4.01 of its Form 8-K dated March 18, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Delcath Systems, Inc. contained |
|
| March 6, 2025 |
Delcath Systems, Inc. Policy On Insider Trading Last reviewed: March 1, 2022 In the course of conducting the business of Delcath Systems, Inc. (the "Company"), we may come into possession of material information about the Company or other entities that is not available to the investing public ("material nonpublic information"). You must maintain the confidentiality of material nonpublic informatio |
|
| March 6, 2025 |
Exhibit 21 SUBSIDIARIES OF THE REGISTRANT 1.Delcath Systems Limited, organized under the laws of Ireland. 2.Delcath UK Systems Limited, organized under the laws of England. 3.Delcath Systems GmbH, organized under the laws of Germany. 4.Delcath Systems B.V., organized under the laws of the Netherlands. |
|
| March 6, 2025 |
Exhibit 4.12 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our common stock and preferred stock summarizes the material terms and provisions of our common stock and preferred stock. The following description of our capital stock does not purport to be complete and is subject to, and qualified in its |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 DELCATH SYSTEMS, INC. |
|
| March 6, 2025 |
Exhibit 99.1 Delcath Systems Reports Fourth Quarter and Full Year 2024 Results Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY – March 6, 2025, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the f |
|
| March 6, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2024 o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 001-16133 DELCATH SY |
|
| January 27, 2025 |
EX-99.A BD-DIR-RESOL 2 exaDCTH13DA.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13D/A with respect to the beneficial ownership of shares of Common Stock of Delcath Systems, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: D |
|
| January 13, 2025 |
Exhibit 99.2 Corporate Presentation NASDAQ: DCTH January 2025 Forward-Looking Statement The Private Securities Litigation Reform Act of 1995 provides a safe harbor for ability to successfully enter into any necessary purchase and sale agreements with users of forward-looking statements made by the Company or on its behalf. This the HEPZATO KIT; the timing and results of the Company’s clinical tria |
|
| January 13, 2025 |
Exhibit 99.1 Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results Fourth Quarter Revenue Approximately $15.1 Million and Full Year Total Revenue Approximately $37.2 Million QUEENSBURY, NY – January 13, 2025, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic ca |
|
| January 13, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 DELCATH SYSTEMS, INC. |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 Delcath Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-16133 06-1245881 (State or other jurisdiction of incorporation) (Commission |
|
| December 30, 2024 |
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises Exhibit 99.1 Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises QUEENSBURY, NY – December 30, 2024, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the exercise of 1.7 million Series E and E1 warrants which |
|
| December 30, 2024 |
EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT DELCATH SYSTEMS, INC. Warrant Shares: [•] Issue Date: December 23, 2024 Initial Exercise Date: December 23, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [•], or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions here |
|
| November 14, 2024 |
DCTH / Delcath Systems, Inc. / Rosalind Advisors, Inc. Activist Investment SC 13D/A 1 rosalinddcth13da12oct.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 12) (Rule 13d-101) Under the Securities Exchange Act of 1934 Delcath Systems, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 24661P807 (CUSIP Number) 566 Queensbury Avenue, Queensbury, New York 12804 (Name, Address and Telephone Number of Pe |
|
| November 14, 2024 |
DCTH / Delcath Systems, Inc. / Rosalind Advisors, Inc. Activist Investment SC 13D/A 1 rosalinddcth13da12oct.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 12) (Rule 13d-101) Under the Securities Exchange Act of 1934 Delcath Systems, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 24661P807 (CUSIP Number) 566 Queensbury Avenue, Queensbury, New York 12804 (Name, Address and Telephone Number of Pe |
|
| November 14, 2024 |
SC 13G/A 1 sc13ga207422dcth11142024.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Delcath Systems, Inc. (Name of Issuer) Common Stock, $0.01 par val |
|
| November 14, 2024 |
SC 13G/A 1 ea022116108-13ga1vivodelca.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Delcath Systems, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 24661P807 (CUSIP Number) September 30, 2024 (Date of Event Which Req |
|
| November 14, 2024 |
EX-99.A BD-DIR-RESOL 2 exaDCTH13DA.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13D/A with respect to the beneficial ownership of shares of Common Stock of Delcath Systems, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: D |
|
| November 14, 2024 |
EX-99.A BD-DIR-RESOL 2 exaDCTH13DA.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13D/A with respect to the beneficial ownership of shares of Common Stock of Delcath Systems, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: D |
|
| November 8, 2024 |
DCTH / Delcath Systems, Inc. / HIRSCHMAN ORIN Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No.1 Under the Securities Exchange Act of 1934 Delcath Systems, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 24661P807 (CUSIP Number) November 5, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-1613 |
|
| November 8, 2024 |
Exhibit 99.1 Delcath Systems Reports Third Quarter 2024 Results and Business Highlights Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY – November 8, 2024, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highligh |
|
| November 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 DELCATH SYSTEMS, INC. |
|
| October 17, 2024 |
Exhibit 99.1 Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results $10 Million Quarterly U.S. Revenue Triggers $25 Million Financing Tranche QUEENSBURY, NY – October 17, 2024, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary re |
|
| October 17, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 DELCATH SYSTEMS, INC. |
|
| September 26, 2024 |
DELCATH SYSTEMS, INC. 2,762,657 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-236100 PROSPECTUS DELCATH SYSTEMS, INC. 2,762,657 Shares of Common Stock This prospectus relates to the re-sale by the selling stockholders identified in this prospectus (each a “Selling Stockholder” and, collectively, the “Selling Stockholders”) of up to an aggregate of 2,762,657 shares of common stock, $0.01 par value per sh |
|
| September 26, 2024 |
Table of Contents PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-235904 DELCATH SYSTEMS, INC. 1,851,900 Shares of Common Stock Issuable Upon Exercise of Outstanding Series F Warrants 17,456 Shares of Common Stock Issuable Upon Exercise of Outstanding Pre-Funded Warrants This prospectus relates to the offer and sale by us of an aggregate 1,851,900 of our shares of common stock, $0 |
|
| September 18, 2024 |
As filed with the Securities and Exchange Commission on September 18, 2024 Table of Contents As filed with the Securities and Exchange Commission on September 18, 2024 Registration No. |
|
| September 18, 2024 |
Power of Attorney (see signature page to the Existing Registration Statement) Table of Contents As filed with the Securities and Exchange Commission on September 18, 2024 Registration No. |
|
| August 29, 2024 |
Exhibit 99.1 Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients NEW YORK - August 28, 2024 Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of a clinical study in the |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 Delcath Systems, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16133 06-1245881 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 28, 2024 |
EX-99.2 Exhibit 99.2 Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients NEW YORK, August 27, 2024—Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company specializing in the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective study b |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2024 Delcath Systems, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16133 06-1245881 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 28, 2024 |
EX-99.1 Exhibit 99.1 Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors NEW YORK, August 26, 2024 — Delcath Systems, Inc. (Nasdaq: DCTH) (“Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of an independent study condu |
|
| August 5, 2024 |
Exhibit 10.1 FIFTH AMENDMENT TO THE LICENSE, SUPPLY AND CONTRACT MANUFACTURING AGREEMENT This Fifth Amendment to the License, Supply, and Contract Manufacturing Agreement ("Fifth Amendment") is made and entered into as of May 1, 2024 ("Fifth Amendment Effective Date") between Synerx Pharma, LLC, a Pennsylvania limited liability company (“Synerx”) and Mylan Teoranta, a limited company formed under |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-16133 DEL |
|
| August 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 DELCATH SYSTEMS, INC. |
|
| August 5, 2024 |
Exhibit 99.1 Delcath Systems Reports Second Quarter 2024 Results and Business Highlights Company Reports $7.8 million in Quarterly Revenue Conference Call Today at 4:30pm Eastern Time QUEENSBURY, NY – August 5, 2024, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today re |
|
| August 1, 2024 |
Delcath Systems, Inc. 566 Queensbury Avenue, Queensbury, New York 12804 Delcath Systems, Inc. 566 Queensbury Avenue, Queensbury, New York 12804 August 1, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Robert Augustin Re: Delcath Systems, Inc. Registration Statement on Form S-3 Filed June 28, 2024 File No. 333-280551 To whom it may conc |
|
| July 19, 2024 |
Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into by and between Delcath Systems, Inc. (“Company”) and the employee whose signature appears below, who is referred to as “Executive.” The Agreement’s Effective Date shall be the date on which the Agreement has been (1) fully executed by the Parties and (2) approved by the Company’s Board of Directors (“Boar |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 Delcath Systems, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16133 06-1245881 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| July 19, 2024 |
4, by and between Delcath Systems, Inc. and Sandra Pennell (incorporated by reference Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into by and between Delcath Systems, Inc. (“Company”) and the employee whose signature appears below, who is referred to as “Executive.” The Agreement’s Effective Date shall be the date on which the Agreement has been (1) fully executed by the Parties and (2) approved by the Company’s Board of Directors (“Boar |
|
| July 19, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into by and between Delcath Systems, Inc. (“Company”) and the employee whose signature appears below, who is referred to as “Executive.” The Agreement’s Effective Date shall be the date on which the Agreement has been (1) fully executed by the Parties and (2) approved by the Company’s Board of Directors (“Boar |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 Delcath Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-16133 06-1245881 (State or other jurisdiction of incorporation) (Commission File |
|
| June 28, 2024 |
As filed with the Securities and Exchange Commission on June 28, 2024 As filed with the Securities and Exchange Commission on June 28, 2024 Registration No. |
|
| June 28, 2024 |
As filed with the Securities and Exchange Commission on June 28, 2024 As filed with the Securities and Exchange Commission on June 28, 2024 Registration No. |
|
| June 28, 2024 |
Exhibit 4.1 DELCATH SYSTEMS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [], 20 Debt Securities Table Of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Sectio |
|
| June 28, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Delcath Systems, Inc. |
|
| June 28, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) DELCATH SYSTEMS, INC. |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Delcath Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-16133 06-1245881 (State or other jurisdiction of incorporation) (Commission File |
|
| May 29, 2024 |
Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath’s Board of Directors EX-99.1 Exhibit 99.1 Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath’s Board of Directors NEW YORK, May 28, 2024 Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company’s Board |
|
| May 29, 2024 |
2020 Omnibus Equity Incentive Plan, as amended EX-10.1 Exhibit 10.1 DELCATH SYSTEMS, INC. 2020 OMNIBUS EQUITY INCENTIVE PLAN (As adopted by Board of Directors on September 30, 2020 and approved by stockholders on November 23, 2020) (As amended by the Board of Directors on March 30, 2021 and approved by stockholders on May 6, 2021) (As subsequently amended by the Board of Directors on April 17, 2023 and approved by stockholders on June 12, 2023 |
|
| May 17, 2024 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13D/A with respect to the beneficial ownership of shares of Common Stock of Delcath Systems, Inc. |
|
| May 17, 2024 |
DCTH / Delcath Systems, Inc. / Rosalind Advisors, Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 10) (Rule 13d-101) Under the Securities Exchange Act of 1934 Delcath Systems, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 24661P807 (CUSIP Number) 566 Queensbury Avenue, Queensbury, New York 12804 (Name, Address and Telephone Number of Person Authorized to Receive Notices an |
|
| May 14, 2024 |
Exhibit 99.1 Delcath Systems Reports First Quarter 2024 Results and Business Highlights Conference Call Today at 8:30am Eastern Time QUEENSBURY – May 14, 2024, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 DELCATH SYSTEMS, INC. |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-16133 DE |
|
| May 9, 2024 |
1,918,140 Shares of Common Stock Offered by the Selling Stockholders Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-278989 1,918,140 Shares of Common Stock Offered by the Selling Stockholders This prospectus relates to the offer and resale, from time to time, by the selling stockholders named under the heading “Selling Stockholders” in this prospectus, or their assigns (the “Selling Stockholders”), of 1,918,140 shares (the “Shares”) of the |
|
| May 8, 2024 |
As filed with the Securities and Exchange Commission on May 8, 2024 S-3/A As filed with the Securities and Exchange Commission on May 8, 2024 Registration No. |
|
| May 8, 2024 |
Delcath Systems, Inc. 566 Queensbury Avenue, Queensbury, New York 12804 Delcath Systems, Inc. 566 Queensbury Avenue, Queensbury, New York 12804 May 8, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Juan Grana Re: Delcath Systems, Inc. Registration Statement on Form S-3 Filed April 29, 2024 File No. 333-278989 To whom it may concern |
|
| April 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Delcath Systems, Inc. |
|
| April 29, 2024 |
As filed with the Securities and Exchange Commission on April 29, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 29, 2024 Registration No. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 DELCATH SYSTEMS, INC. |
|
| April 12, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Under § 240. |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive Additional Materials o Soliciting Material Under § 240. |
|
| March 26, 2024 |
Exhibit 21 SUBSIDIARIES OF THE REGISTRANT 1.Delcath Systems Limited, organized under the laws of Ireland. 2.Delcath UK Systems Limited, organized under the laws of England. 3.Delcath Systems GmbH, organized under the laws of Germany. 4.Delcath Systems B.V., organized under the laws of the Netherlands. |
|
| March 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023 o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 001-16133 DELCATH SY |
|
| March 26, 2024 |
Exhibit 99.1 Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update Increases 2024 Treatment Site Activation Guidance to 20 Sites QUEENSBURY – March 26, 2024, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported recent busi |
|
| March 26, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 DELCATH SYSTEMS, INC. |
|
| March 26, 2024 |
Exhibit 97 DELCATH SYSTEMS, INC. Incentive Compensation Recoupment Policy Introduction The Compensation and Stock Option Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Delcath Systems, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment |
|
| March 26, 2024 |
Exhibit 4.12 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our common stock and preferred stock summarizes the material terms and provisions of our common stock and preferred stock. The following description of our capital stock does not purport to be complete and is subject to, and qualified in its |
|
| March 25, 2024 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13D/A with respect to the beneficial ownership of shares of Common Stock of Delcath Systems, Inc. |
|
| March 25, 2024 |
DCTH / Delcath Systems, Inc. / Rosalind Advisors, Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 10) (Rule 13d-101) Under the Securities Exchange Act of 1934 Delcath Systems, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 24661P807 (CUSIP Number) 566 Queensbury Avenue, Queensbury, New York 12804 (Name, Address and Telephone Number of Person Authorized to Receive Notices an |
|
| March 19, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 14, 2024, by and between DELCATH SYSTEMS, INC., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Pu |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 DELCATH SYSTEMS, INC. |
|
| March 19, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. THIS SECURITY AND THE SECURIT |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 DELCATH SYSTEMS, INC. |
|
| March 19, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 14, 2024, between DELCATH SYSTEMS, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| March 19, 2024 |
Delcath Systems Announces $7 Million Private Placement Exhibit 99.1 Delcath Systems Announces $7 Million Private Placement March 15, 2024 NEW YORK, March 15, 2024 /PRNewswire/ — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that it has entered into a securities purchase agreement with certain accredited investors comprised of existing in |
|
| March 19, 2024 |
Delcath Systems Appoints Martha S. Rook as Chief Operating Officer Exhibit 99.1 Delcath Systems Appoints Martha S. Rook as Chief Operating Officer Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Martha S. Rook as its new Chief Operating Officer (COO). Martha S. Rook, Ph.D., is an experienced indus |
|
| February 14, 2024 |
SC 13G/A 1 sc13ga107422dcth02142024.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Delcath Systems, Inc. (Name of Issuer) Common Stock, $0.01 par val |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2024 DELCATH SYSTEMS, INC. |
|
| February 13, 2024 |
DCTH / Delcath Systems, Inc. / Stonepine Capital Management, LLC Passive Investment SC 13G/A 1 dcth13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Delcath Systems, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 24661P807 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 13, 2024 |
SC 13G/A 1 ea193540-13ga1vivodelcath.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Delcath Systems, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 24661P807 (CUSIP Number) December 31, 2023 (Date of Event Which Requi |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Delcath Systems, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 24661P807 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| January 31, 2024 |
Delcath Systems Receives Permanent EX-99.1 Exhibit 99.1 Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024 NEWS PROVIDED BY Delcath Systems, Inc. ☐ 31 Jan, 2024, 08:00 ET NEW YORK, Jan. 31, 2024 /PRNewswire/ — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today a |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 DELCATH SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16133 06-1245881 (State or other jurisdiction of incorporation) (Commission |
|
| January 9, 2024 |
DCTH / Delcath Systems, Inc. / HIRSCHMAN ORIN Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Delcath Systems, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 24661P807 (CUSIP Number) December 27, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| January 8, 2024 |
EX-99.1 Exhibit 99.1 Corporate Presentation NASDAQ: DCTH January 2024 Table of Contents Forward-Looking Statement 3 Investment Summary 4 Unmet Need: Liver-Dominant Cancers 5 HEPZATO KIT™ 8 Metastatic Uveal Melanoma (mUM) 11 FOCUS Trial 16 HEPZATO KIT: Commercialization 20 Reimbursement & Pricing 25 Next Steps: Future Indications 30 References 39 2 Forward-Looking Statement The Private Securities L |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 DELCATH SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16133 06-1245881 (State or other jurisdiction of incorporation) (Commission F |
|
| December 15, 2023 |
EX-99.4 Exhibit 99.4 DELCATH SYSTEMS, INC. INDUCEMENT AWARD STOCK OPTION AGREEMENT (Non-Qualified Stock Option) THIS INDUCEMENT AWARD STOCK OPTION AWARD AGREEMENT (this “Agreement”) is made as of the Date of Award (the “Grant Date”), as defined under the Notice of Inducement Award, by and between Delcath Systems, Inc., a Delaware corporation (the “Company”), and the Recipient (the “Optionee”). The |
|
| December 15, 2023 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 Delcath Systems, Inc. |
|
| December 15, 2023 |
As filed with the Securities and Exchange Commission on December 15, 2023 S-8 As filed with the Securities and Exchange Commission on December 15, 2023 Registration No. |
|
| December 15, 2023 |
Exhibit 99.3 DELCATH SYSTEMS, INC. 2023 INDUCEMENT PLAN STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT is made as of the Date of Grant (the “Grant Date”), as defined under the Stock Option Grant Notice (the “Grant Notice”), by and between Delcath Systems, Inc., a Delaware corporation (the “Company”), and the Participant (the “Optionee”). The parties hereto agree as follows: 1. Inducement Award |
|
| December 15, 2023 |
s Registration Statement on Form S-8 filed with the Commission on December 15, 2023). EX-99.2 Exhibit 99.2 DELCATH SYSTEMS, INC. 2023 INDUCEMENT PLAN (As adopted by Board of Directors on December 5, 2023) 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Na |
|
| November 28, 2023 |
EX-99.A BD-DIR-RESOL 2 exaDCTH13DA9Nov23.htm ROSALINDADVISORSEXA Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13D/A with respect to the beneficial ownership of shares of Common Stock of Delcath Systems, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Na |
|
| November 28, 2023 |
DCTH / Delcath Systems Inc / Rosalind Advisors, Inc. - ROSALINDADVISORS13DA09 Activist Investment SC 13D/A 1 rosalinddcth13da9nov2023.htm ROSALINDADVISORS13DA09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 9) (Rule 13d-101) Under the Securities Exchange Act of 1934 Delcath Systems, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 24661P807 (CUSIP Number) 1633 Broadway,22nd Floor, Suite C, New York, NY 10019 (Name, Addre |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 DELCATH SYSTEMS, INC. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-1613 |
|
| November 13, 2023 |
Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update Exhibit 99.1 Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update NEW YORK – November 13, 2023, Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 202 |
|
| September 6, 2023 |
EX-99.1 Corporate Presentation (NASDAQ: DCTH) September 6, 2023 1 Exhibit 99.1 The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those descri |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 DELCATH SYSTEMS, INC. |
|
| September 1, 2023 |
Up to 19,509,302 Shares of Common Stock Offered by the Selling Stockholders Filed Pursuant to Rule 424(b)(3) Registration No. 333-272659 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus Dated June 28, 2023) Up to 19,509,302 Shares of Common Stock Offered by the Selling Stockholders This Prospectus Supplement No. 1 (this “Prospectus Supplement”) is being filed to update and supplement the information contained in the “Selling Stockholders” section of the Delcath Systems, Inc. (t |
|
| August 16, 2023 |
DCTH / Delcath Systems Inc / Soleus Capital Master Fund, L.P. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Delcath Systems, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 24661P807 (CUSIP Number) August 15, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| August 16, 2023 |
EX-99.A EXHIBIT A JOINT FILING AGREEMENT Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendmen |
|
| August 15, 2023 |
EX-99.2 Exhibit 99.2 Corporate Presentation (NASDAQ: DCTH) August 14, 2023 1 Forward-looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ mat |
|
| August 15, 2023 |
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT EX-99.1 Exhibit 99.1 Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma Approval includes treatment naïve and previously treated patients and is not limited by HLA genotype Delcath to hold Business |
|
| August 15, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 DELCATH SYSTEMS, INC. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 DELCATH SYSTEMS, INC. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-16133 DEL |
|
| August 9, 2023 |
Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update Exhibit 99.1 Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update NEW YORK – August 9, 2023 Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2023. Rece |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 DELCATH SYSTEMS, INC. |
|
| June 28, 2023 |
Up to 19,509,749 Shares of Common Stock Offered by the Selling Stockholders 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-272659 Up to 19,509,749 Shares of Common Stock Offered by the Selling Stockholders This prospectus relates to the offer and resale, from time to time, by the selling stockholders named under the heading “Selling Stockholders” in this prospectus, or their assigns (the “Selling Stockholders”), of up to 19,509,749 shares (t |
|
| June 26, 2023 |
Delcath Systems, Inc. 1633 Broadway, Suite 22C New York, New York 10019 CORRESP Delcath Systems, Inc. 1633 Broadway, Suite 22C New York, New York 10019 June 26, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Re: Delcath Systems, Inc. Registration Statement on Form S-3 Filed June 15, 2023 File No. 333-272659 To whom it may con |
|
| June 26, 2023 |
DCTH / Delcath Systems Inc / Stonepine Capital Management, LLC Passive Investment SC 13G 1 dcth13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Delcath Systems, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 24661P807 (CUSIP Number) June 12, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| June 22, 2023 |
DCTH / Delcath Systems Inc / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Delcath Systems, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 24661P807 (CUSIP Number) June |
|
| June 22, 2023 |
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EX-99.1 Exhibit 99.1 Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW YORK, June 21, 2023 /PRNewswire/ Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s C |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 DELCATH SYSTEMS, INC. |
|
| June 22, 2023 |
DCTH / Delcath Systems Inc / Vivo Opportunity Fund Holdings, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Delcath Systems, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 24661P807 (CUSIP Number) June 12, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| June 22, 2023 |
EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| June 22, 2023 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated June 22, 2023 with respect to the Common Stock, $0.01 par value per share, of Delcath Systems, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the |
|
| June 15, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Delcath Systems, Inc. |
|
| June 15, 2023 |
As filed with the Securities and Exchange Commission on June 14, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 14, 2023 Registration No. |
|
| June 13, 2023 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DELCATH SYSTEMS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Delcath Systems, Inc., a Delaware corporation (hereinafter called the “Corporation”), does hereby certify: FIRST: Upon the filing and effectiveness pursuant to the General Corporation Law of the |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 Delcath Systems, Inc. (Exact name of registrant as specified in its charter) Delaware 001-16133 06-1245881 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 13, 2023 |
2020 Omnibus Equity Incentive Plan, as amended EX-10.1 Exhibit 10.1 DELCATH SYSTEMS, INC. 2020 OMNIBUS EQUITY INCENTIVE PLAN (As adopted by Board of Directors on September 30, 2020 and approved by stockholders on November 23, 2020) (As amended by the Board of Directors on March 30, 2021 and approved by stockholders on May 6, 2021) (As subsequently amended by the Board of Directors on April 17, 2023, and approved by stockholders on June 12, 202 |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 DELCATH SYSTEMS, INC. |
|
| June 7, 2023 |
Delcath Systems Announces Sandra Pennell as Senior Vice President of Finance EX-99.1 Exhibit 99.1 Delcath Systems Announces Sandra Pennell as Senior Vice President of Finance NEW YORK, June 7, 2023 Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that the Company has appointed Sandra Pennell as its new Senior Vice President of |
|
| May 22, 2023 |
EX-10.3 Exhibit 10.3 FIRST AMENDMENT TO LOAN DOCUMENTS This First Amendment to Loan Documents (this “Amendment”) is entered into as of March 31, 2023, by and among AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware limited partnership (“Lender”) and DELCATH SYSTEMS, INC., a Delaware corporation (“Borrower”). RECITALS Borrower, Agent and Lender are parties to those certain Loan Documents, dated as |
|
| May 22, 2023 |
Amended and Restated By-Laws of the Company. EX-3.6 Exhibit 3.6 AMENDED AND RESTATED BY-LAWS OF DELCATH SYSTEMS, INC. A Delaware Corporation ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Annual Meeting. A meeting of stockholders shall be held annually for the election of directors and the transaction of such other business as may properly come before the meeting. Such meeting shall be held at such time and at such place either within or with |
|
| May 22, 2023 |
EX-4.5 Exhibit 4.5 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF (A) SUCH REGISTRATION, (B) |
|
| May 22, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-16133 DE |
|
| May 12, 2023 |
EX-99.1 Exhibit 99.1 Delcath Systems Provides Business Update and Reports Preliminary First Quarter 2023 Financial Results NEW YORK – May 12, 2023, Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and certain preliminary financial results fo |
|
| May 12, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 DELCATH SYSTEMS, INC. |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-K ☐ Transition Report on F |
|
| May 1, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Under § 240. |
|
| May 1, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Under § 240. |
|
| April 21, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Under § 240. |
|
| March 30, 2023 |
Form of Common Tranche B Warrant EX-4.4 6 d377148dex44.htm EX-4.4 Exhibit 4.4 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) I |
|
| March 30, 2023 |
EX-3.1 Exhibit 3.1 DELCATH SYSTEMS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES F CONVERTIBLE VOTING PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW DELCATH SYSTEMS, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby c |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 DELCATH SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16133 08-1245881 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 30, 2023 |
Form of Preferred Tranche B Warrant EX-4.2 Exhibit 4.2 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON CONVERSION OR EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES AND THE SECURITIES ISSUABLE UPON CONVERSION OR EXERCISE OF THESE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) |
|
| March 30, 2023 |
Delcath Systems Announces Closing of Private Placement of up to $85 Million EX-99.2 Exhibit 99.2 Delcath Systems Announces Closing of Private Placement of up to $85 Million Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by existing investor, Rosalind Advisors $25 million financing upfront with up to an additional $60 million tied to satisfaction of milestones Aggregate financ |
|
| March 30, 2023 |
Delcath Systems Announces up to $85 Million Financing EX-99.1 Exhibit 99.1 Delcath Systems Announces up to $85 Million Financing Led by Vivo Capital with participation from Logos Capital, BVF Partners, Stonepine Capital Management, LLC, Serrado Capital and supported by existing investor, Rosalind Advisors $25 million financing upfront with up to an additional $60 million tied to satisfaction of milestones Aggregate financing is sufficient to fund Com |
|
| March 30, 2023 |
EX-10.2 Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 27, 2023, by and among Delcath Systems, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each |
|
| March 30, 2023 |
Form of Common Tranche A Warrant EX-4.3 Exhibit 4.3 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EF |
|
| March 30, 2023 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 27, 2023, by and among Delcath Systems, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each |
|
| March 30, 2023 |
Form of Preferred Tranche A Warrant EX-4.1 Exhibit 4.1 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON CONVERSION OR EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES AND THE SECURITIES ISSUABLE UPON CONVERSION OR EXERCISE OF THESE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 DELCATH SYSTEMS, INC. |
|
| March 28, 2023 |
EX-99.1 Exhibit 99.1 Corporate Presentation (NASDAQ: DCTH) March 26, 2023 Forward-looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materi |
|
| March 27, 2023 |
Delcath Systems Announces up to $85 Million Financing EX-99.1 Exhibit 99.1 Delcath Systems Announces up to $85 Million Financing Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by existing investor, Rosalind Advisors $25 million financing upfront with up to an additional $60 million tied to satisfaction of milestones Aggregate financing expected to be suf |
|
| March 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHA N GE COMMISSION WASHINGTON, D. |
|
| March 27, 2023 |
EX-21 EXHIBIT 21 SUBSIDIARIES OF THE REGISTRANT 1. Delcath Holdings Limited, organized under the laws of Ireland. 2. Delcath Systems Limited, organized under the laws of Ireland. 3. Delcath UK Systems Limited, organized under the laws of England. 4. Delcath Systems GmbH, organized under the laws of Germany. 5. Delcath Systems B.V., organized under the laws of the Netherlands. |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 DELCATH SYSTEMS, INC. |
|
| March 27, 2023 |
EX-4.12 EXHIBIT 4.12 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our common stock and preferred stock summarizes the material terms and provisions of our common stock and preferred stock. The following description of our capital stock does not purport to be complete and is subject to, and qualified |
|
| February 27, 2023 |
Up to $17,000,000 Common Stock 424B5 Filed pursuant to Rule 424(b)(5) Registration No. 333-257428 Prospectus Supplement (To Prospectus Supplement dated November 9, 2021) Up to $17,000,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus supplement, dated November 9, 2021, filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File No |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 DELCATH SYSTEMS, INC. |
|
| February 14, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 DELCATH SYSTEMS, INC. |
|
| February 14, 2023 |
Delcath Systems Announces New Drug Application Resubmission for HEPZATO Kit Exhibit 99.1 Delcath Systems Announces New Drug Application Resubmission for HEPZATO Kit NEW YORK, February 14, 2023/PRNewswire/ - Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced it submitted a new drug application (NDA) resubmission to the US Food and Drug Administration (FDA) for the HEPZA |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2023 DELCATH SYSTEMS, INC. |
|
| January 20, 2023 |
Up to 2,140,931 Shares of Common Stock Offered by the Selling Stockholders Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-269173 Up to 2,140,931 Shares of Common Stock Offered by the Selling Stockholders This prospectus relates to the offer and resale, from time to time, by the selling stockholders named under the heading “Selling Stockholders” in this prospectus, or their assigns (the “Selling Stockholders”), of up to 2,140,931 shares of the Com |
|
| January 18, 2023 |
Delcath Systems, Inc. 1633 Broadway, Suite 22C New York, New York 10019 CORRESP 1 filename1.htm Delcath Systems, Inc. 1633 Broadway, Suite 22C New York, New York 10019 January 18, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Benjamin Ritchie Re: Delcath Systems, Inc. Registration Statement on Form S-3 Filed January 10, 2023 File No. |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 DELCATH SYSTEMS, INC. |
|
| January 10, 2023 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Delcath Systems, Inc. |
|
| January 10, 2023 |
As filed with the Securities and Exchange Commission on January 10, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on January 10, 2023 Registration No. |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 DELCATH SYSTEMS, INC. |
|
| January 3, 2023 |
EX-99.1 Corporate Presentation (NASDAQ: DCTH) January 2023 Exhibit 99.1 The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Fa |
|
| December 29, 2022 |
DCTH / Delcath Systems Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| December 21, 2022 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Delcath Systems, Inc. |
|
| December 21, 2022 |
DCTH / Delcath Systems Inc / Rosalind Advisors, Inc. - DELCATH SC 13 D/A 8 Activist Investment SC 13D/A delcath13da8.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 8) (Rule 13d-101) Under the Securities Exchange Act of 1934 Delcath Systems, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 24661P807 (CUSIP Number) 1633 Broadway,22nd Floor, Suite C, New York, NY 10019 (Name, Address and Telephone Number of P |
|
| December 16, 2022 |
DCTH / Delcath Systems Inc / MICHEL GERARD J - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Delcath Systems, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 24661P807 (CUSIP Number) McCarter & English, LLP Four Gateway Center 100 Mulberry Street Newark, New Jersey 07102 Attention: Veronica H. Montagn |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 DELCATH SYSTEMS, INC. |
|
| December 13, 2022 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 13, 2022 |
Delcath Systems Closes Private Placement of $6.2 Million Exhibit 99.2 Delcath Systems Closes Private Placement of $6.2 Million NEW YORK, December 13, 2022 ? Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the closing of the previously announced private placement with certain accredited investors (the ?Private Placement?). Delcath issued and |
|
| December 13, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of December 7, 2022, between Delcath Systems, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and condition |
|
| December 13, 2022 |
Delcath Systems Announces Private Placement of $6.2 Million Exhibit 99.1 Delcath Systems Announces Private Placement of $6.2 Million NEW YORK, December 8, 2022 ? Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that it has entered into a securities purchase agreement with certain accredited investors for a private placement transaction (the ?Pri |
|
| December 13, 2022 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of December 7, 2022, by and between Delcath Systems, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities |
|
| November 8, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-1613 |
|
| October 28, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 DELCATH SYSTEMS, INC. |
|
| September 15, 2022 |
Up to 1,257,705 Shares of Common Stock Offered by the Selling Stockholders Table of Contents Filed pursuant to 424(b)(3) Registration Statement No. 333-267321 Up to 1,257,705 Shares of Common Stock Offered by the Selling Stockholders This prospectus relates to the offer and resale, from time to time, by the selling stockholders named under the heading ?Selling Stockholders? in this prospectus, or their assigns (the ?Selling Stockholders?), of up to 1,257,705 shares of th |
|
| September 13, 2022 |
Delcath Systems, Inc. 1633 Broadway, Suite 22C New York, New York 10019 Delcath Systems, Inc. 1633 Broadway, Suite 22C New York, New York 10019 September 13, 2022 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Delcath Systems, Inc. Registration Statement on Form S-3 Filed September 7, 2022 File No. 333-267321 To whom it may concern: Pursuant to |
|
| September 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 DELCATH SYSTEMS, INC. |
|
| September 12, 2022 |
Exhibit 99.1 Corporate Presentation (NASDAQ: DCTH) September 2022 Forward-looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially fro |
|
| September 7, 2022 |
EX-FILING FEES 4 d329205dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Delcath Systems, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price |
|
| September 7, 2022 |
As filed with the Securities and Exchange Commission on September 7, 2022 Table of Contents As filed with the Securities and Exchange Commission on September 7, 2022 Registration No. |
|
| August 8, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-16133 DEL |
|
| July 27, 2022 |
DCTH / Delcath Systems Inc / MICHEL GERARD J - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Delcath Systems, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 24661P807 (CUSIP Number) McCarter & English, LLP Four Gateway Center 100 Mulberry Street Newark, New Jersey 07102 Attention: Veronica H. Montagna |
|
| July 21, 2022 |
DCTH / Delcath Systems Inc / Rosalind Advisors, Inc. - DELCATH SC 13 D/A 7 Activist Investment SC 13D/A delcath13da7.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 7) (Rule 13d-101) Under the Securities Exchange Act of 1934 Delcath Systems, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 24661P807 (CUSIP Number) 1633 Broadway,22nd Floor, Suite C, New York, NY 10019 (Name, Address and Telephone Number of P |
|
| July 21, 2022 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Delcath Systems, Inc. |
|
| July 20, 2022 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 20, 2022 |
EX-99.2 6 d385139dex992.htm EX-99.2 Exhibit 99.2 Delcath Systems Announces Private Placement of $5.0 Million NEW YORK, July 18, 2022 — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that it has entered into a securities purchase agreement with certain accredited investors for a privat |
|
| July 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2022 DELCATH SYSTEMS, INC. |
|
| July 20, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 18, 2022, between Delcath Systems, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions s |
|
| July 20, 2022 |
Delcath Systems Closes Private Placement of $5.0 Million Exhibit 99.1 Delcath Systems Closes Private Placement of $5.0 Million NEW YORK, July 20, 2022 ? Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the closing of the previously announced private placement for the issuance and sale of 690,954 shares of common stock (the ?Common Stock?) and |
|
| July 20, 2022 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of July 18, 2022, by and between Delcath Systems, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Pur |
|
| June 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2022 DELCATH SYSTEMS, INC. |
|
| June 7, 2022 |
Exhibit 99.1 Corporate Presentation (NASDAQ: DCTH) June 2022 Forward-looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from tho |
|
| June 7, 2022 |
Exhibit 99.2 Positive Initial Results from CHOPIN Phase 1b Trial, FOCUS Trial Update and QoL Study Presented at the 2022 ASCO Annual Meeting Initial results from the Phase 1b portion of the CHOPIN trial of PHP in combination with ipilimumab plus nivolumab in advanced uveal melanoma in seven patients resulted in 85.7% Best Overall Response and 100% Disease Control Rate. Median progression free surv |
|
| May 25, 2022 |
Calculation of Filing Fee Table EXHIBIT 107.1 Calculation of Filing Fee Table FORM S-8 (Form Type) DELCATH SYSTEMS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par valu |
|
| May 25, 2022 |
As filed with the Securities and Exchange Commission on May 25, 2022 As filed with the Securities and Exchange Commission on May 25, 2022 Registration No. |
|
| May 25, 2022 |
Delcath Systems, Inc. 2021 Employee Stock Purchase Plan Exhibit 4.10 DELCATH SYSTEMS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN (As adopted by the Board of Directors on August 5, 2021 and approved by the stockholders on May 4, 2022) The purpose of the Delcath Systems, Inc. 2021 Employee Stock Purchase Plan (the ?Plan?) is to provide eligible employees of Delcath Systems, Inc. (the ?Company?) and each Designated Subsidiary (as defined in Section 11) with o |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 DELCATH SYSTEMS, INC. |
|
| May 11, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-16133 DE |
|
| May 11, 2022 |
Exhibit 99.1 Delcath Systems Reports First Quarter 2022 Results and Provides Business Update NEW YORK ? Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the first quarter ended March 31, 2022. Recent Business Highlights During and since the f |
|
| May 6, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 DELCATH SYSTEMS, INC. |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ? 240. |
|
| March 31, 2022 |
EXHIBIT 21 SUBSIDIARIES OF THE REGISTRANT 1. Delcath Holdings Limited, organized under the laws of Ireland. 2. Delcath Systems Limited, organized under the laws of Ireland. 3. Delcath UK Systems Limited, organized under the laws of England. 4. Delcath Systems GmbH, organized under the laws of Germany. 5. Delcath Systems B.V., organized under the laws of the Netherlands. |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 001-16133 DELCATH SYSTEMS, INC. Delawa |
|
| March 31, 2022 |
EX-4.9 2 d663303dex49.htm EX-4.9 EXHIBIT 4.9 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our common stock and preferred stock summarizes the material terms and provisions of our common stock and preferred stock. The following description of our capital stock does not purport to be complete and is s |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2022 DELCATH SYSTEMS, INC. |
|
| March 29, 2022 |
Exhibit 99.1 Delcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update NEW YORK ? Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter and full-year ended December 31, 2021. Recent Business |
|
| March 9, 2022 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of Delcath Systems, Inc. |
|
| March 9, 2022 |
DCTH / Delcath Systems Inc / Rosalind Advisors, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 6) (Rule 13d-101) Under the Securities Exchange Act of 1934 Delcath Systems, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 24661P807 (CUSIP Number) 1633 Broadway, 22nd Floor, Suite C, New York, NY 10019 (Name, Address and Telephone Number of Person Authorized to Receive Notice |
|
| February 14, 2022 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13D/A with respect to the beneficial ownership of shares of Common Stock of Delcath Systems, Inc. |
|
| February 14, 2022 |
DCTH / Delcath Systems Inc / Rosalind Advisors, Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 5) (Rule 13d-101) Under the Securities Exchange Act of 1934 Delcath Systems, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 24661P807 (CUSIP Number) 1633 Broadway,22nd Floor, Suite C, New York, NY 10019 (Name, Address and Telephone Number of Person Authorized to Receive Notices |
|
| February 8, 2022 |
DCTH / Delcath Systems Inc / SILVERARC CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Delcath Systems, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 24661P807 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| January 6, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 DELCATH SYSTEMS, INC. |
|
| January 5, 2022 |
As filed with the Securities and Exchange Commission on January 5, 2022 As filed with the Securities and Exchange Commission on January 5, 2022 Registration No. |
|
| January 5, 2022 |
Exhibit 4.9 DELCATH SYSTEMS, INC. 2020 OMNIBUS EQUITY INCENTIVE PLAN (As adopted by Board of Directors on September 30, 2020 and approved by stockholders on November 23, 2020) (As amended by the Board of Directors on March 30, 2021 and approved by stockholders on May 6, 2021) 1. Purpose. The purpose of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan (the ?Plan?) is to align the intere |
|
| December 2, 2021 |
Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato Exhibit 99.2 Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato? in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis On final analysis of the primary overall response (ORR) endpoint, HEPZATO further exceeded the predefined threshold for success with a median duration of response of 14 months While overall survival data continues to m |
|
| December 2, 2021 |
Corporate Presentation (NASDAQ: DCTH) December 2021 Exhibit 99.1 The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors t |
|
| December 2, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 DELCATH SYSTEMS, INC. |
|
| November 10, 2021 |
Exhibit 99.1 Delcath Systems Announces Third Quarter 2021 Results November 9, 2021 NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) ? Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2021. Recent Business Hi |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 DELCATH SYSTEMS, INC. |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-16133 DELCATH SYSTEMS, |
|
| November 9, 2021 |
Up to $25,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257428 PROSPECTUS SUPPLEMENT (To Prospectus dated July 2, 2021) Up to $25,000,000 Common Stock We previously entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our common stock, $0.01 par value per share, offered by this pro |
|
| October 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2021 DELCATH SYSTEMS, INC. |
|
| October 18, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2021 DELCATH SYSTEMS, INC. |
